| TUŽIL, Jan, Tomáš MLČOCH, Jitka JIRČÍKOVÁ, Jakub ZÁVADA, Lucie NEKVINDOVÁ, Michal SVOBODA, Michal UHER, Zlatuše KŘÍSTKOVÁ, Jiří VENCOVSKÝ, Karel PAVELKA and Tomáš DOLEŽAL. Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. Expert Opinion on Biological Therapy. TAYLOR & FRANCIS, 2020, vol. 20, No 2, p. 183-192. ISSN 1471-2598. Available from: https://dx.doi.org/10.1080/14712598.2020.1694900. |
Other formats:
BibTeX
LaTeX
RIS
@article{1615386,
author = {Tužil, Jan and Mlčoch, Tomáš and Jirčíková, Jitka and Závada, Jakub and Nekvindová, Lucie and Svoboda, Michal and Uher, Michal and Křístková, Zlatuše and Vencovský, Jiří and Pavelka, Karel and Doležal, Tomáš},
article_number = {2},
doi = {http://dx.doi.org/10.1080/14712598.2020.1694900},
keywords = {Ankylosing spondylitis; BASDAI; ASDAS; anti-TNF; work impairment; disability; predictive power; multivariate modeling},
language = {eng},
issn = {1471-2598},
journal = {Expert Opinion on Biological Therapy},
title = {Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry},
url = {https://www.tandfonline.com/doi/full/10.1080/14712598.2020.1694900},
volume = {20},
year = {2020}
}
TY - JOUR
ID - 1615386
AU - Tužil, Jan - Mlčoch, Tomáš - Jirčíková, Jitka - Závada, Jakub - Nekvindová, Lucie - Svoboda, Michal - Uher, Michal - Křístková, Zlatuše - Vencovský, Jiří - Pavelka, Karel - Doležal, Tomáš
PY - 2020
TI - Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry
JF - Expert Opinion on Biological Therapy
VL - 20
IS - 2
SP - 183-192
EP - 183-192
PB - TAYLOR & FRANCIS
SN - 14712598
KW - Ankylosing spondylitis
KW - BASDAI
KW - ASDAS
KW - anti-TNF
KW - work impairment
KW - disability
KW - predictive power
KW - multivariate modeling
UR - https://www.tandfonline.com/doi/full/10.1080/14712598.2020.1694900
L2 - https://www.tandfonline.com/doi/full/10.1080/14712598.2020.1694900
N2 - Objectives: To assess the role of short-term response to first anti-TNF in long-term prediction of disability. Methods: In nationwide registry ATTRA, we identified ankylosing spondylitis patients starting anti-TNF between 01/2003 and 12/2016. Full disability and work impairment (WI; WPAI questionnaire) were predicted via the Cox- and lagged-parameter mixed-effect regression. Results: 2,274 biologicals-naive patients newly indicated to anti-TNF were prospectively followed (6,333 patient-years; median follow-up 1.9 years). Reaching BASDAI < 4 (77.4%) and ASDAS-CRP < 2.1 (61.1%) after 3 months of anti-TNF both decreased the risk of future disability by approximate to 2.5-fold. ASDAS-CRP < 2.1 predicted non-disability better than BASDAI < 4 & CRP < 5 mg/L (p = 0.032). BASDAI < 4 & CRP < 5 mg/L was comparable to BASDAI < 4 (p = 0.941) and to BASDAI change by >50% or by >2 points (p = 0.902). ASDAS-CRP change >1.1 and >2.0 both failed to predict non-disability. Once on anti-TNF therapy, the strongest predictor of WI was Pain (SF36). Yearly increase in indirect costs remains below euro3,000 in those reaching ASDAS-CRP < 2.1. Conclusions: Low disease activity measured by ASDAS-CRP <= 2.1 should be used to measure the outcome of new anti-TNF therapy. Continuous WI could be decreased through pain management.
ER -
TUŽIL, Jan, Tomáš MLČOCH, Jitka JIRČÍKOVÁ, Jakub ZÁVADA, Lucie NEKVINDOVÁ, Michal SVOBODA, Michal UHER, Zlatuše KŘÍSTKOVÁ, Jiří VENCOVSKÝ, Karel PAVELKA and Tomáš DOLEŽAL. Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. \textit{Expert Opinion on Biological Therapy}. TAYLOR \&{} FRANCIS, 2020, vol.~20, No~2, p.~183-192. ISSN~1471-2598. Available from: https://dx.doi.org/10.1080/14712598.2020.1694900.
|
